Hepatobiliary Cancers | Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposium Review
MAR 21
Description Community
About
Featuring perspectives from Dr Robin (Katie) Kelley and Dr Mark Yarchoan, including the following topics: 
  • Introduction: Interdisciplinary Management of Hepatocellular Carcinoma (HCC) in the Community (General Medical Oncology) Setting — Radiology, Hepatology, Pathology Support (0:00)
  • Potential Role of Anti-PD-1/PD-L1 Antibodies in the Care of Patients with Early- and Intermediate-Stage HCC — Dr Yarchoan (8:09)
  • HCC Rounds (22:07)
  • Tolerability and Other Practical Considerations with the Use of Immune Checkpoint Inhibitors for Advanced HCC and Biliary Tract Cancers (BTCs) — Dr Kelley (39:25)
  • Faculty Survey (49:19)
  • BTC Rounds (52:19)

 

Comments